AAAAAA

   
Results: 1-9 |
Results: 9
On the initial trigger of myasthenia gravis and suppression of the diseaseby antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope
Authors: Atassi, MZ Oshima, M Deitiker, P
Citation: Mz. Atassi et al., On the initial trigger of myasthenia gravis and suppression of the diseaseby antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope, CR R IMMUN, 21(1-3), 2001, pp. 1-27
Special issue: Papers from the 10th International Symposium on the Immunobiology of Proteins and Peptides - Preface
Authors: Bixler, GS Atassi, MZ
Citation: Gs. Bixler et Mz. Atassi, Special issue: Papers from the 10th International Symposium on the Immunobiology of Proteins and Peptides - Preface, CR R IMMUN, 21(1-3), 2001, pp. V-VI
T cells of mice treated with mPEG-myasthenogenic peptide conjugate are involved in protection against EAMG by stimulating lower pathogenic antibody responses
Authors: Oshima, M Atassi, MZ
Citation: M. Oshima et Mz. Atassi, T cells of mice treated with mPEG-myasthenogenic peptide conjugate are involved in protection against EAMG by stimulating lower pathogenic antibody responses, AUTOIMMUN, 32(1), 2000, pp. 45-55
Antigen mimicry in autoimmune disease. Can immune responses to microbial antigens that mimic acetylcholine receptor act as initial triggers of myasthenia gravis?
Authors: Deitiker, P Ashizawa, T Atassi, MZ
Citation: P. Deitiker et al., Antigen mimicry in autoimmune disease. Can immune responses to microbial antigens that mimic acetylcholine receptor act as initial triggers of myasthenia gravis?, HUMAN IMMUN, 61(3), 2000, pp. 255-265
Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T-cell epitope
Authors: Nakayashiki, N Oshima, M Deitiker, PR Ashizawa, T Atassi, MZ
Citation: N. Nakayashiki et al., Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T-cell epitope, J NEUROIMM, 105(2), 2000, pp. 131-144
Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins
Authors: Atassi, MZ Oshima, M
Citation: Mz. Atassi et M. Oshima, Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins, CR R IMMUN, 19(3), 1999, pp. 219-260
Subunit interacting surfaces of human hemoglobin in solution: Localizationof the alpha-beta subunit interacting surfaces on the alpha-chain by a comprehensive synthetic strategy
Authors: Yoshioka, N Atassi, MZ
Citation: N. Yoshioka et Mz. Atassi, Subunit interacting surfaces of human hemoglobin in solution: Localizationof the alpha-beta subunit interacting surfaces on the alpha-chain by a comprehensive synthetic strategy, J PROTEIN C, 18(2), 1999, pp. 179-185
Capacity of antibodies to synthetic peptides of alpha-bungarotoxin for recognizing conformational sections of the neurotoxin molecule
Authors: Dolimbek, BZ Atassi, MZ
Citation: Bz. Dolimbek et Mz. Atassi, Capacity of antibodies to synthetic peptides of alpha-bungarotoxin for recognizing conformational sections of the neurotoxin molecule, CHEM NAT CO, 35(4), 1999, pp. 448-451
In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies
Authors: Abaza, MS Shaban, FA Narayan, RK Atassi, MZ
Citation: Ms. Abaza et al., In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies, BR J CANC, 78(12), 1998, pp. 1578-1585
Risultati: 1-9 |